aglepristone
Description
aglepristone: Alizine is tradename [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 14153279 |
CHEMBL ID | 2103998 |
CHEBI ID | 177608 |
SCHEMBL ID | 2108967 |
MeSH ID | M0377411 |
Synonyms (20)
Synonym |
---|
CHEBI:177608 |
(8s,11r,13s,14s,17r)-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-17-[(z)-prop-1-enyl]-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one |
aglepristone (inn) |
alizine (tn) |
124478-60-0 |
D07096 |
aglepristone |
aglepristone [inn] |
unii-0ut4jle1cm |
0ut4jle1cm , |
11beta-(p-(dimethylamino)phenyl)-17beta-hydroxy-17-((z)-propenyl)estra-4,9-dien-3-one |
aglepristone [mi] |
11.beta.-(p-(dimethylamino)phenyl)-17.beta.-hydroxy-17-((z)-propenyl)estra-4,9-dien-3-one |
aglepristone [mart.] |
CHEMBL2103998 |
alizine |
AKOS025311442 |
SCHEMBL2108967 |
4-methyl-2-pyridin-2-yl-1,3-thiazole-5-carboxylicacid |
DTXSID001016632 |
Research Excerpts
Overview
Aglepristone (RU534) is an antiprogestin used for pregnancy termination, parturition induction and conservative pyometra treatment in bitches. Agle Pristone is a safe abortifacient in cats, dogs and rabbits.
Excerpt | Reference | Relevance |
---|---|---|
"Aglepristone is a safe abortifacient in cats, dogs and rabbits. " | ( Clinical, ultrasonography and haematology of aglepristone-induced mid-gestation pregnancy terminations in rabbits. Özalp, GR; Özocak-Batmaz, E; Temizel, EM, 2013) | 2.09 |
"Aglepristone (RU534) is an antiprogestin used for pregnancy termination, parturition induction and conservative pyometra treatment in bitches. " | ( Lack of in vitro effect of aglepristone on IFN-γ and IL-4 production by resting and mitogen-activated T cells of luteal bitches. Borkowska, J; Jurka, P; Szulc-Dąbrowska, L; Winnicka, A, 2013) | 2.13 |
"Aglepristone (RU 46534) is a competitive progesterone antagonist that is indicated for the treatment of various progesterone-dependent physiological or pathologic conditions. " | ( Aglepristone: A review on its clinical use in animals. Fiéni, F; Gogny, A, 2016) | 3.32 |
Treatment
Aglepristone treatment in mid-gestation had no effect on IGF1 and IGF1R mRNA levels. Treatment caused substantial downregulation of luteal LEP expression by 72 h post-treatment (P ≤ 0.01)
Compound-Compound Interactions
Excerpt | Reference | Relevance |
---|---|---|
" For this purpose we compared the effects of aglepristone (AGL) alone and in combination with cloprostenol (CLO) on serum concentrations of progesterone (P4), estradiol (E2) and relaxin (RLN) measured at short-term intervals during the abortion period in bitches." | ( The effects of aglepristone alone and in combination with cloprostenol on hormonal values during termination of mid-term pregnancy in bitches. Ağaoğlu, AR; Aslan, S; Ay, SS; Bal, Y; Einspanier, A; Emre, B; Gültiken, N; Gürcan, IS; Kaya, D; Küçükaslan, I; Schäfer-Somi, S, 2014) | 1.02 |
Drug Classes (1)
Class | Description |
---|---|
oxo steroid | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (82)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 32 (39.02) | 29.6817 |
2010's | 46 (56.10) | 24.3611 |
2020's | 4 (4.88) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 58.20
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (58.20) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 20 (23.81%) | 5.53% |
Reviews | 2 (2.38%) | 6.00% |
Case Studies | 5 (5.95%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 57 (67.86%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |